BIOHIT'S FINANCIAL STATEMENTS AND REPORT OF BOARD OF DIRECTORS FOR 2009 PUBLISHED
BIOHIT OYJ STOCK EXCHANGE RELEASE ON 31 MARCH 2010 AT 6:45 PM
BIOHIT'S FINANCIAL STATEMENTS AND REPORT OF BOARD OF DIRECTORS FOR 2009 HAVE BEEN PUBLISHED The financial statements, the report of the Board of Directors, including the Corporate Governance statement, and the auditor's report of Biohit Oyj for the financial year 2009 have been published today in Finnish and English on Biohit's web site at www.biohit.com/investors, and as attachment to this release. The Annual Report 2009, which also includes the above mentioned documents, as well as the annual summary will be published in Finnish and English on Biohit's web site during week 16 the latest. Hardcopies of the Annual Report may be ordered from Biohit, via telephone: +358-9-7738 61, via email comms@biohit.com or via the order form at Biohit's website. ANNUAL SUMMARY OF STOCK EXCHANGE RELEASES An annual summary of Biohit Oyj's stock exchange releases and announcements published in 2009 is available at www.biohit.com/exreleases. Additionally, the summary is published in the Annual Report. The website also includes all other stock exchange releases and announcements published by Biohit since 1999. Some of the information included in the releases might be out of date. Jussi Heiniö VP, Administration and Legal Affairs Biohit Oyj Further information: Jussi Heiniö VP, Administration and Legal Affairs Tel: +358-9-7738 6223 Email: jussi.heinio@biohit.com Distribution: NASDAQ OMX Helsinki Oy Central storage facility (www.oam.fi) Press www.biohit.com About Biohit Oyj Established in 1988, Biohit Oyj is a Finnish biotechnology company, acting on the global market. Biohit's operations are based on a goal-oriented and long-term innovation and patenting strategy. Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective liquid handling solutions for laboratory work as well as diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract. Biohit has two business segments: liquid handling and diagnostics. Liquid handling products include electronic and mechanical pipettes, disposable tips as well as pipette maintenance and calibration services for research institutions, healthcare and industrial laboratories. The diagnostics business comprises products and analysis systems for the early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and H. pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of intestinal bleeding that indicates a risk of colorectal cancer. The Acetium innovation reduces carcinogenic acetaldehyde in anacidic stomachs. The Biohit Group employs around 370 people. The company is headquartered in Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia, India, China, Japan and the USA, as well as a representative office in Singapore. Additionally, Biohit's products are sold by approximately 450 distributors in 70 countries. Biohit's series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small cap/Healthcare since 1999. Read more at www.biohit.com